-48%

est. 2Y upside i

Cybersecurity

MedCrypt gives medical device vendors cybersecurity features in a few…

Rank

#3247

Sector

Cybersecurity

Est. Liquidity

~3Y

Data Quality

Data: Low

MedCrypt offers strong regulatory moat and a large TAM, but the equity proposition is poor due to an estimated $40M valuation being exceeded by $44.7M in total funding, implying a severe preference overhang.

Last updated: July 3, 2026

Bull (10%)+39%

MedCrypt maintains its strong regulatory moat and gains market share; exit multiple holds at 16.7x on projected $3.8M revenue, yielding a $63.7M valuation. After 20% dilution, upside is 39.25%.

Base (50%)-24%

Multiple converges to public comp average of 10x on $3.8M revenue, implying $38.2M valuation—below entry. After 20% dilution, downside is -24.45%.

Bear (40%)-100%

Multiple compresses to 6x on $3.8M revenue, implying $22.9M exit—below $44.7M preferred liquidation preference; common stock recovers -100%.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

11175%

Total funding of $44.7M exceeds estimated valuation of $40M, implying common stock may have little value in an exit below that level.

Dilution Risk

high

Company likely needs to raise additional capital within 24 months, diluting current equity by ~20%.

Secondary Liquidity

none

No secondary market observed.

Questions to Ask at the Interview

Strategic questions based on MedCrypt's data — designed to show you've done your homework.

  • 1

    “How does MedCrypt plan to differentiate from large incumbents like Palo Alto Networks as they enter healthcare IoT?”

  • 2

    “What is the company's path to profitability given $2.4M revenue and $44.7M raised?”

  • 3

    “Given the preference stack, what is the realistic timeline and vehicle for liquidity?”

Community

Valuation Sentiment

Our model estimates -48% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.